On the public citation graph
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
0 signed · 3845 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/jama.290.16.2149openalex-snapshot
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer
inferredcites →https://doi.org/10.1002/(sici)1096-987x(19981115)19:14<1639::aid-jcc10>3.0.co;2-bopenalex-snapshot
Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function
inferredcites →https://doi.org/10.1016/s0006-2952(98)00356-6openalex-snapshot
Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with In Vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785)
inferredcites →https://doi.org/10.1016/s0092-8674(03)00190-9openalex-snapshot
Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL
inferredcites →https://doi.org/10.1056/nejmoa011954openalex-snapshot
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa040938openalex-snapshot
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
inferredcites →https://doi.org/10.1073/pnas.0405220101openalex-snapshot
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
inferredcites →https://doi.org/10.1074/jbc.m207135200openalex-snapshot
Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor
inferredcites →https://doi.org/10.1074/jbc.m211158200openalex-snapshot
Mutation of Threonine 766 in the Epidermal Growth Factor Receptor Reveals a Hotspot for Resistance Formation against Selective Tyrosine Kinase Inhibitors
inferredcites →https://doi.org/10.1107/s0907444904011679openalex-snapshot
PRODRG: a tool for high-throughput crystallography of protein–ligand complexes
inferredcites →https://doi.org/10.1126/science.1062538openalex-snapshot
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
inferredcites →https://doi.org/10.1126/science.1099314openalex-snapshot
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
inferredcites →https://doi.org/10.1126/science.1099480openalex-snapshot
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
inferredcites →https://doi.org/10.1126/science.1101637openalex-snapshot
Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways
inferredcites →https://doi.org/10.1158/0008-5472.can-04-0085openalex-snapshot
A Missense Mutation in KIT Kinase Domain 1 Correlates with Imatinib Resistance in Gastrointestinal Stromal Tumors
inferredcites →https://doi.org/10.1200/jco.20.1.110openalex-snapshot
Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor Inhibition
inferredcites →https://doi.org/10.1200/jco.2002.02.068openalex-snapshot
Phase III Randomized Trial Comparing Three Platinum-Based Doublets in Advanced Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1200/jco.2003.01.504openalex-snapshot
Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer
inferredcites →https://doi.org/10.1200/jco.2003.10.038openalex-snapshot
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1200/jco.2004.08.158openalex-snapshot
Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1200/jco.2004.11.057openalex-snapshot
Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1200/jco.2005.07.169openalex-snapshot
Unusual Cases in Multiple Myeloma and a Dramatic Response in Metastatic Lung Cancer
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.3970228openalex-extracted
A scRNA-seq Based Prediction Model of EGFR-TKIs Resistance in Patients With Non-Small Cell Lung Adenocarcinoma
inferred← citeshttps://doi.org/10.2139/ssrn.4051300openalex-extracted
Design and Synthesis of Proteolysis Targeting Chimeras (Protacs) as an Egfr Degrader Based on Co-1686
inferred← citeshttps://doi.org/10.2139/ssrn.4597996openalex-extracted
Inhibition of IFITM1 Transcription a New Mechanism for FoxO3a Suppressing Stemness in NSCLC
inferred← citeshttps://doi.org/10.1001/jama.2019.11058openalex-snapshot
Systemic Therapy for Locally Advanced and Metastatic Non–Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1001/jama.298.1.70openalex-snapshot
Therapies Directed Against Epidermal Growth Factor Receptor in Aerodigestive Carcinomas
inferred← citeshttps://doi.org/10.1002/0471141755.ph0209s60openalex-snapshot
The Human Kinome and Kinase Inhibition
inferred← citeshttps://doi.org/10.1002/0471142905.hg1009s50openalex-snapshot
EGF Receptor Testing for Non‐Small Cell Lung Carcinomas
inferred← citeshttps://doi.org/10.1002/0471266949.bmc222openalex-snapshot
Structure‐Based Design of Kinase Inhibitors: Molecular Recognition of Protein Multiple Conformations
inferred← citeshttps://doi.org/10.1002/0471463736.tnmp49openalex-snapshot
Incorporating Molecular Oncology into Prognosis
inferred← citeshttps://doi.org/10.1002/1873-3468.12166openalex-snapshot
Weak binding to E3 ubiquitin ligase c‐Cbl increases EGFRvA protein stability
inferred← citeshttps://doi.org/10.1002/1878-0261.12055openalex-snapshot
MAP4K4 is a novel MAPK/ERK pathway regulator required for lung adenocarcinoma maintenance
inferred← citeshttps://doi.org/10.1002/9780470015902.a0000659.pub2openalex-snapshot
Protein Kinases: Signatures in Cancer
inferred← citeshttps://doi.org/10.1002/9780470015902.a0026709openalex-snapshot
D arwinian Evolution of Tumours
inferred← citeshttps://doi.org/10.1002/9780470025079.chap86.pub2openalex-snapshot
Modern Approaches to Radiation Therapy
inferred← citeshttps://doi.org/10.1002/9780470025079.chap96.pub2openalex-snapshot
Rational Drug Design of Small Molecule Anticancer Agents: Preclinical Discovery
inferred← citeshttps://doi.org/10.1002/9780470696330.ch22openalex-snapshot
Epidermal Growth Factor Receptor Inhibitors
inferred← citeshttps://doi.org/10.1002/9780470696330.ch4openalex-snapshot
The Molecular Genetics of Lung Cancer
inferred← citeshttps://doi.org/10.1002/9781118468678.ch34openalex-snapshot
Targeting the c‐Met Kinase
inferred← citeshttps://doi.org/10.1002/9781118468791.ch27openalex-snapshot
Mechanisms of Resistance to Epidermal Growth Factor Receptor (EGFR) in Non‐Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1002/9781118468791.ch4openalex-snapshot
Somatic Genome Alterations in Human Lung Cancers
inferred← citeshttps://doi.org/10.1002/9781118482490.ch1openalex-snapshot
Structural Bases of Protein Kinase CK2 Function and Inhibition
inferred← citeshttps://doi.org/10.1002/9781118684535.ch19openalex-snapshot
Interaction between Targeted Therapy and Immunotherapy
inferred← citeshttps://doi.org/10.1002/9781119000822.hfcm017.pub2openalex-snapshot
Tumor Angiogenesis
inferred← citeshttps://doi.org/10.1002/9781119000822.hfcm046openalex-snapshot
Principles of Medical Oncology
inferred← citeshttps://doi.org/10.1002/9781119060208.ch4openalex-snapshot
Signal Transduction in Disease
inferred← citeshttps://doi.org/10.1002/9781119300229.ch2openalex-snapshot
The Role of HGF / MET and MSP / RON Signaling in Tumor Progression and Resistance to Anticancer Therapy
inferred← citeshttps://doi.org/10.1002/9781119341154.ch2openalex-snapshot
Radiation Biology for Radiation Oncologists
inferred← citeshttps://doi.org/10.1002/9781394376490.ch16openalex-snapshot
Targeted Therapy and Personalized Treatment Approaches
inferred← citeshttps://doi.org/10.1002/9783527619375.ch15bopenalex-snapshot
Chemical Biology of Kinases Studied by NMR Spectroscopy
inferred← citeshttps://doi.org/10.1002/9783527677252.ch02openalex-snapshot
Discovery of Predictive Biomarkers for Anticancer Drugs
inferred← citeshttps://doi.org/10.1002/9783527808694.ch12openalex-snapshot
The Discovery of Osimertinib ( TAGRISSO ™): An Irreversible Inhibitor of Activating and T790M Resistant Forms of the Epidermal Growth Factor Receptor Tyrosine Kinase for the Treatment of Non‐Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1002/9783527818242.ch6openalex-snapshot
Reverse Translation to Support Efficient Drug Target Selection and Stratified Medicine
inferred← citeshttps://doi.org/10.1002/9783527840748.ch6openalex-snapshot
QM / MM for Structure‐Based Drug Design: Techniques and Applications
inferred← citeshttps://doi.org/10.1002/adfm.201400456openalex-snapshot
Synergistic Enhancement of Lung Cancer Therapy Through Nanocarrier‐Mediated Sequential Delivery of Superantigen and Tyrosin Kinase Inhibitor
inferred← citeshttps://doi.org/10.1002/adhm.201100005openalex-snapshot
Cooperative, Nanoparticle‐Enabled Thermal Therapy of Breast Cancer
inferred← citeshttps://doi.org/10.1002/advs.202001442openalex-snapshot
Injectable Thermosensitive Hydrogel Containing Erlotinib‐Loaded Hollow Mesoporous Silica Nanoparticles as a Localized Drug Delivery System for NSCLC Therapy
inferred← citeshttps://doi.org/10.1002/advs.202505785openalex-snapshot
EGFR: New Insights on Its Activation and Mutation in Tumor and Tumor Immunotherapy
inferred← citeshttps://doi.org/10.1002/ange.201302313openalex-snapshot
Pyrimido[4,5‐ d ]pyrimidin‐4(1 H )‐one Derivatives as Selective Inhibitors of EGFR Threonine 790 to Methionine 790 (T790M) Mutants
inferred← citeshttps://doi.org/10.1002/ange.201605011openalex-snapshot
Inhibition wirkstoffresistenter Mutationsvarianten der Rezeptortyrosinkinase EGFR
inferred← citeshttps://doi.org/10.1002/ange.201802416openalex-snapshot
Eine strukturelle Evaluierung medizinalchemischer Strategien gegen Wirkstoffresistenzen
inferred← citeshttps://doi.org/10.1002/anie.201302313openalex-snapshot
Pyrimido[4,5‐d]pyrimidin‐4(1H)‐one Derivatives as Selective Inhibitors of EGFR Threonine790 to Methionine790 (T790M) Mutants
inferred← citeshttps://doi.org/10.1002/anie.201605011openalex-snapshot
Insight into the Inhibition of Drug‐Resistant Mutants of the Receptor Tyrosine Kinase EGFR
inferred← citeshttps://doi.org/10.1002/anie.201802416openalex-snapshot
A Structural View on Medicinal Chemistry Strategies against Drug Resistance
inferred← citeshttps://doi.org/10.1002/ardp.200800009openalex-snapshot
The Development of HKI‐272 and Related Compounds for the Treatment of Cancer
inferred← citeshttps://doi.org/10.1002/ardp.201600063openalex-snapshot
Covalent EGFR Inhibitors: Binding Mechanisms, Synthetic Approaches, and Clinical Profiles
inferred← citeshttps://doi.org/10.1002/ardp.201800037openalex-snapshot
Overcoming resistance in non‐small‐cell lung cancer: A practical lesson for the medicinal chemist
inferred← citeshttps://doi.org/10.1002/ardp.201800110openalex-snapshot
Synthesis and antitumor evaluation of novel 4‐anilino‐7,8‐dihydropyrido[4,3‐d]pyrimidine‐6(5H)‐carboxylate derivatives as potential EGFR inhibitors
inferred← citeshttps://doi.org/10.1002/ardp.202400992openalex-snapshot
A Structural Insight Into Two Important ErbB Receptors (EGFR and HER2) and Their Relevance to Non‐Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1002/ardp.70061openalex-snapshot
From Lab to Target: Pyrazole, Pyrazoline and Fused Pyrazole Derivatives as Receptor Tyrosine Kinase Inhibitors in Cancer Therapy
inferred← citeshttps://doi.org/10.1002/ardp.70193openalex-snapshot
HBE‐843, a Novel, Potent, and Selective EGFR Targeting PROTAC for the Treatment of Non‐Small‐Cell Lung Cancer
inferred← citeshttps://doi.org/10.1002/biot.200800110openalex-snapshot
Novel human antibody therapeutics: The age of the Umabs
inferred← citeshttps://doi.org/10.1002/bip.23274openalex-snapshot
Peptoid drug discovery and optimization via surface X‐ray scattering
inferred← citeshttps://doi.org/10.1002/bjs.6176openalex-snapshot
Molecularly targeted therapy and cancer surgery
inferred← citeshttps://doi.org/10.1002/bmc.5059openalex-snapshot
Development of a sensitive UHPLC–MS/MS method for the pharmacokinetics study of a novel tyrosine kinase inhibitors, 1‐[4‐(4‐{5‐Chloro‐4‐[2‐(propane‐2‐sulfonyl)‐phenylamino]‐pyrimidin‐2‐ylamino}‐phenyl)‐piperazin‐1‐yl]‐propenone in rats
inferred← citeshttps://doi.org/10.1002/cam4.1667openalex-snapshot
Emerging findings into molecular mechanism of brain metastasis
inferred← citeshttps://doi.org/10.1002/cam4.2244openalex-snapshot
Profiling of circulating tumor DNA in plasma of non‐small cell lung cancer patients, monitoring of epidermal growth factor receptor p.T790M mutated allelic fraction using beads, emulsion, amplification, and magnetics companion assay and evaluation in future application in mimicking circulating…
inferred← citeshttps://doi.org/10.1002/cam4.2913openalex-snapshot
Effect of anlotinib as a third‐ or further‐line therapy in advanced non‐small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial
inferred← citeshttps://doi.org/10.1002/cam4.3639openalex-snapshot
Suppression of tumor immune microenvironment via microRNA‐1 after epidermal growth factor receptor‐tyrosine kinase inhibitor resistance acquirement in lung adenocarcinoma
inferred← citeshttps://doi.org/10.1002/cam4.413openalex-snapshot
Activity of second‐generation ALK inhibitors against crizotinib‐resistant mutants in an NPM‐ALK model compared to EML4‐ALK
inferred← citeshttps://doi.org/10.1002/cam4.6942openalex-snapshot
Schizandrin A induces non‐small cell lung cancer apoptosis by suppressing the epidermal growth factor receptor activation
inferred← citeshttps://doi.org/10.1002/cam4.71592openalex-snapshot
Clinical Progression Modes of Crizotinib Failure and Subsequent Management of Advanced Non‐Small Cell Lung Cancer With ROS 1 Rearrangement
inferred← citeshttps://doi.org/10.1002/cam4.978openalex-snapshot
A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR‐TKI resistance
inferred← citeshttps://doi.org/10.1002/cbdv.201600372openalex-snapshot
Recent Development of the Second and Third Generation Irreversible Epidermal Growth Factor Receptor Inhibitors
inferred← citeshttps://doi.org/10.1002/cbdv.201800518openalex-snapshot
Covalent vs. Non‐Covalent Inhibition: Tackling Drug Resistance in EGFR – A Thorough Dynamic Perspective
inferred← citeshttps://doi.org/10.1002/cbic.201000352openalex-snapshot
Characterization of Irreversible Kinase Inhibitors by Directly Detecting Covalent Bond Formation: A Tool for Dissecting Kinase Drug Resistance
inferred← citeshttps://doi.org/10.1002/cbic.201600115openalex-snapshot
Monitoring Conformational Changes in the Receptor Tyrosine Kinase EGFR
inferred← citeshttps://doi.org/10.1002/cbin.11962openalex-snapshot
Targeting BET proteins inhibited the growth of non‐small cell lung carcinoma through downregulation of Met expression
inferred← citeshttps://doi.org/10.1002/chem.201705181openalex-snapshot
Discovery of Potent EGFR Inhibitors through the Incorporation of a 3D‐Aromatic‐Boron‐Rich‐Cluster into the 4‐Anilinoquinazoline Scaffold: Potential Drugs for Glioma Treatment
inferred← citeshttps://doi.org/10.1002/cmdc.201000384openalex-snapshot
Discovery of 4‐Benzylamino‐Substituted α‐Carbolines as a Novel Class of Receptor Tyrosine Kinase Inhibitors
inferred← citeshttps://doi.org/10.1002/cncr.22133openalex-snapshot
Clinical implications of the mechanism of epidermal growth factor receptor inhibitors
inferred← citeshttps://doi.org/10.1002/cncr.22207openalex-snapshot
Clinical factors affecting acquired resistance to gefitinib in previously treated Japanese patients with advanced nonsmall cell lung cancer
inferred← citeshttps://doi.org/10.1002/cncr.22903openalex-snapshot
Epidermal growth factor ligand/receptor loop and downstream signaling activation pattern in completely resected nonsmall cell lung cancer
inferred← citeshttps://doi.org/10.1002/cncr.23925openalex-snapshot
Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications
inferred← citeshttps://doi.org/10.1002/cncr.26225openalex-snapshot
The rise and fall of gatekeeper mutations? The BCR‐ABL1 T315I paradigm
inferred← citeshttps://doi.org/10.1002/cncr.27575openalex-snapshot
Phase 1 dose‐escalation trial evaluating the combination of the selective MET (mesenchymal‐epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib
inferred← citeshttps://doi.org/10.1002/cncr.28290openalex-snapshot
Volumetric tumor growth in advanced non‐small cell lung cancer patients with EGFR mutations during EGFR‐tyrosine kinase inhibitor therapy
inferred← citeshttps://doi.org/10.1002/cncr.28364openalex-snapshot
Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor
inferred← citeshttps://doi.org/10.1002/cncr.28711openalex-snapshot
Clinical outcome according to the level of preexisting epidermal growth factor receptor T790M mutation in patients with lung cancer harboring sensitive epidermal growth factor receptor mutations
inferred← citeshttps://doi.org/10.1002/cncr.28723openalex-snapshot
Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non‐small cell lung cancer
inferred← citeshttps://doi.org/10.1002/cncr.28725openalex-snapshot
The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non–small cell lung cancer
inferred← citeshttps://doi.org/10.1002/cncr.28864openalex-snapshot
The MAPK pathway across different malignancies: A new perspective
inferred← citeshttps://doi.org/10.1002/cncr.28964openalex-snapshot
Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor‐sensitizing and resistance mutations in the plasma DNA of patients with advanced non–small cell lung cancer during treatment with erlotinib
inferred← citeshttps://doi.org/10.1002/cncr.29139openalex-snapshot
The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer
inferred← citeshttps://doi.org/10.1002/cncr.31678openalex-snapshot
Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR ‐mutant non–small cell lung cancer: Multicenter, single‐arm, phase 2 trial (ABC Study)
inferred← citeshttps://doi.org/10.1002/cncr.33385openalex-snapshot
Olmutinib in T790M‐positive non–small cell lung cancer after failure of first‐line epidermal growth factor receptor‐tyrosine kinase inhibitor therapy: A global, phase 2 study
inferred← citeshttps://doi.org/10.1002/cncr.35353openalex-snapshot
Commemorating the 20th anniversary of the discovery of epidermal growth factor receptor mutation in lung cancer: Translational research at its best
inferred← citeshttps://doi.org/10.1002/cncr.35778openalex-snapshot
Updates on the treatment of epidermal growth factor receptor‐mutant non–small cell lung cancer
inferred← citeshttps://doi.org/10.1002/cncy.20011openalex-snapshot
EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer
inferred← citeshttps://doi.org/10.1002/cncy.20151openalex-snapshot
EGFR and KRAS mutations in lung carcinoma
inferred← citeshttps://doi.org/10.1002/cpdd.427openalex-snapshot
Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC
inferred← citeshttps://doi.org/10.1002/cso2.70011openalex-snapshot
Identification of Crucial Drug Targets and Pathways to Reprogram Drug Resistance Through Epigenetic Modulation in Advanced Lung Cancer Using Integrated Bioinformatics Approach
inferred← citeshttps://doi.org/10.1002/dc.24193openalex-snapshot
Transformation of lung adenocarcinoma to small cell lung carcinoma in the setting of tyrosine kinase inhibitor therapy: Cytological approach of a clinically challenging phenomenon
inferred← citeshttps://doi.org/10.1002/ddr.20268openalex-snapshot
EGFR inhibition in the treatment of non‐small cell lung cancer
inferred← citeshttps://doi.org/10.1002/dneu.20350openalex-snapshot
Neural precursor cells from a fatal human motoneuron disease differentiate despite aberrant gene expression
inferred← citeshttps://doi.org/10.1002/em.20600openalex-snapshot
Oncomutations as biomarkers of cancer risk
inferred← citeshttps://doi.org/10.1002/emmm.201000070openalex-snapshot
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine
inferred← citeshttps://doi.org/10.1002/gcc.20566openalex-snapshot
Direct resequencing of the completeERBB2coding sequence reveals an absence of activating mutations inERBB2amplified breast cancer
inferred← citeshttps://doi.org/10.1002/gcc.20604openalex-snapshot
Expression and mutational analysis of MET in human solid cancers
inferred← citeshttps://doi.org/10.1002/gcc.22522openalex-snapshot
Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer
inferred← citeshttps://doi.org/10.1002/hep.29350openalex-snapshot
Role of ErbB/HER family of receptor tyrosine kinases in cholangiocyte biology
inferred← citeshttps://doi.org/10.1002/humu.20512openalex-snapshot
Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature
inferred← citeshttps://doi.org/10.1002/humu.21194openalex-snapshot
Inferring the functional effects of mutation through clusters of mutations in homologous proteins
inferred← citeshttps://doi.org/10.1002/ijc.21301openalex-snapshot
EGFR and erbB2 mutation status in Japanese lung cancer patients
inferred← citeshttps://doi.org/10.1002/ijc.21496openalex-snapshot
Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers
inferred← citeshttps://doi.org/10.1002/ijc.21670openalex-snapshot
Frequent EGFR mutations in noninvasive bronchioloalveolar carcinoma
inferred← citeshttps://doi.org/10.1002/ijc.22513openalex-snapshot
The impact of epidermal growth factor receptor gene status on gefitinib‐treated Japanese patients with non‐small‐cell lung cancer
inferred← citeshttps://doi.org/10.1002/ijc.23868openalex-snapshot
EGFR genetic heterogeneity of nonsmall cell lung cancers contributing to acquired gefitinib resistance
inferred← citeshttps://doi.org/10.1002/ijc.24150openalex-snapshot
MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors
inferred← citeshttps://doi.org/10.1002/ijc.24657openalex-snapshot
Second‐line treatments after first‐line gefitinib therapy in advanced nonsmall cell lung cancer
inferred← citeshttps://doi.org/10.1002/ijc.25799openalex-snapshot
Reaction of plasma hepatocyte growth factor levels in non‐small cell lung cancer patients treated with EGFR‐TKIs
inferred← citeshttps://doi.org/10.1002/ijc.26276openalex-snapshot
Antitumor activity of HM781‐36B, a highly effective pan‐HER inhibitor in erlotinib‐resistant NSCLC and other EGFR‐dependent cancer models
inferred← citeshttps://doi.org/10.1002/ijc.26461openalex-snapshot
A novel treatment strategy for EGFR mutant NSCLC with T790M‐mediated acquired resistance
inferred← citeshttps://doi.org/10.1002/ijc.27968openalex-snapshot
Restriction endonuclease‐mediated real‐time digestion‐PCR for somatic mutation detection
inferred← citeshttps://doi.org/10.1002/ijc.28009openalex-snapshot
ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor
inferred← citeshttps://doi.org/10.1002/ijc.28034openalex-snapshot
The novel phosphoinositide 3‐kinase–mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor
inferred← citeshttps://doi.org/10.1002/ijc.29320openalex-snapshot
The combination of irreversible EGFR TKI s and SAHA induces apoptosis and autophagy‐mediated cell death to overcome acquired resistance in EGFR T 790 M ‐mutated lung cancer
inferred← citeshttps://doi.org/10.1002/ijc.30649openalex-snapshot
Induction of Cbl-dependent epidermal growth factor receptor degradation in Ling Zhi-8 suppressed lung cancer
inferred← citeshttps://doi.org/10.1002/ijc.32025openalex-snapshot
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first‐line gefitinib, erlotinib and afatinib‐treated non‐small cell lung cancer patients with activating EGFR mutations
inferred← citeshttps://doi.org/10.1002/ijc.32097openalex-snapshot
Efficacy and safety of osimertinib in treating EGFR‐mutated advanced NSCLC: A meta‐analysis
inferred← citeshttps://doi.org/10.1002/imm3.70057openalex-snapshot
High‐Concordance Detection Across Diverse Biospecimens EGFR Mutation in a Large‐Scale NSCLC Cohort Using Droplet Digital PCR and Next‐Generation Sequencing
inferred← citeshttps://doi.org/10.1002/jbt.22784openalex-snapshot
Strategic targeting of non‐small‐cell lung cancer utilizing genetic material‐based delivery platforms of nanotechnology
inferred← citeshttps://doi.org/10.1002/jbt.70077openalex-snapshot
Design, Synthesis, and Evaluation of Novel 2,4‐disubstituted Pyrimidine Derivatives as Double Mutant Epidermal Growth Factor Receptor‐L858R/T790M Tyrosine Kinase Inhibitors
inferred← citeshttps://doi.org/10.1002/jcb.22888openalex-snapshot
Integrin beta1 over‐expression associates with resistance to tyrosine kinase inhibitor gefitinib in non‐small cell lung cancer
inferred← citeshttps://doi.org/10.1002/jcb.26128openalex-snapshot
Shikonin Inhibited Migration and Invasion of Human Lung Cancer Cells via Suppression of c‐Met‐Mediated Epithelial‐to‐Mesenchymal Transition
inferred← citeshttps://doi.org/10.1002/jcb.29564openalex-snapshot
From clinical specimens to human cancer preclinical models—a journey the NCI‐cell line database—25 years later
inferred← citeshttps://doi.org/10.1002/jccs.201900435openalex-snapshot
Systematic characterization of adenosine triphosphate response to lung cancer epidermal growth factor receptor missense mutations: A molecular insight into “generic” drug resistance mutations
inferred← citeshttps://doi.org/10.1002/jccs.202100217openalex-snapshot
Molecular analysis and systematic profiling of allosteric inhibitor response to clinically significant epidermal growth factor receptor missense mutations in non‐small cell lung cancer
inferred← citeshttps://doi.org/10.1002/jcp.21901openalex-snapshot
Sensing invasion: Cell surface receptors driving spreading of glioblastoma
inferred← citeshttps://doi.org/10.1002/jcp.22647openalex-snapshot
Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways
inferred← citeshttps://doi.org/10.1002/jcp.22895openalex-snapshot
Inhibition of lung cancer growth: ATP citrate lyase knockdown and statin treatment leads to dual blockade of mitogen‐activated protein Kinase (MAPK) and Phosphatidylinositol‐3‐kinase (PI3K)/AKT pathways
inferred← citeshttps://doi.org/10.1002/jcp.25749openalex-snapshot
Biological and pharmacological evaluation of dimethoxycurcumin: A metabolically stable curcumin analogue with a promising therapeutic potential
inferred← citeshttps://doi.org/10.1002/lt.21325openalex-snapshot
Clinical and molecular classification of hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1002/lt.22340openalex-snapshot
Tissue biomarkers as predictors of outcome and selection of transplant candidates with hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1002/mc.20607openalex-snapshot
KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: Implication for combinatorial approach
inferred← citeshttps://doi.org/10.1002/mc.22475openalex-snapshot
Epiregulin is required for lung tumor promotion in a murine two-stage carcinogenesis model
inferred← citeshttps://doi.org/10.1002/mco2.105openalex-snapshot
Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy
inferred← citeshttps://doi.org/10.1002/mco2.342openalex-snapshot
Targeting drug‐tolerant cells: A promising strategy for overcoming acquired drug resistance in cancer cells
inferred← citeshttps://doi.org/10.1002/mco2.694openalex-snapshot
Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies
inferred← citeshttps://doi.org/10.1002/med.21700openalex-snapshot
Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer
inferred← citeshttps://doi.org/10.1002/msj.20220openalex-snapshot
Targeted Inhibition of Kinases in Cancer Therapy
inferred← citeshttps://doi.org/10.1002/path.2645openalex-snapshot
Our changing view of the genomic landscape of cancer
inferred← citeshttps://doi.org/10.1002/path.4273openalex-snapshot
The impact of germline mutations on targeted therapy
inferred← citeshttps://doi.org/10.1002/path.4275openalex-snapshot
The evolving genomic classification of lung cancer
inferred← citeshttps://doi.org/10.1002/path.4278openalex-snapshot
Somatic alterations as the basis for resistance to targeted therapies
inferred← citeshttps://doi.org/10.1002/path.4354openalex-snapshot
An activation of LC3A ‐mediated autophagy contributes to de novo and acquired resistance to EGFR tyrosine kinase inhibitors in lung adenocarcinoma
inferred← citeshttps://doi.org/10.1002/pmic.201400315openalex-snapshot
Identifying novel targets of oncogenic EGF receptor signaling in lung cancer through global phosphoproteomics
inferred← citeshttps://doi.org/10.1002/pro.4125openalex-snapshot
A structural perspective on targeting the RTK /Ras/ MAP kinase pathway in cancer
inferred← citeshttps://doi.org/10.1002/pro.5023openalex-snapshot
A fluorescence‐based sensor for calibrated measurement of protein kinase stability in live cells
inferred← citeshttps://doi.org/10.1002/pros.23945openalex-snapshot
A novel androgen receptor antagonist JJ‐450 inhibits enzalutamide‐resistant mutant ARF876L nuclear import and function
inferred← citeshttps://doi.org/10.1002/prot.21111openalex-snapshot
Impact of EGFR point mutations on the sensitivity to gefitinib: Insights from comparative structural analyses and molecular dynamics simulations
inferred← citeshttps://doi.org/10.1002/prot.26761openalex-snapshot
L858R / L718Q and L858R / L792H Mutations of EGFR Inducing Resistance Against Osimertinib by Forming Additional Hydrogen Bonds
inferred← citeshttps://doi.org/10.1002/psp4.12710openalex-snapshot
Modeling restoration of gefitinib efficacy by co‐administration of MET inhibitors in an EGFR inhibitor‐resistant NSCLC xenograft model: A tumor‐in‐host DEB‐based approach
inferred← citeshttps://doi.org/10.1002/rcr2.597openalex-snapshot
Pulmonary pleomorphic carcinoma with pembrolizumab monotherapy
inferred← citeshttps://doi.org/10.1002/slct.202506601openalex-snapshot
Computational Screening of Indole Metabolites Targeting EGFR Wild‐Type and Mutant Proteins Using Molecular Docking and Molecular Dynamics Simulations
inferred← citeshttps://doi.org/10.1002/smtd.201900357openalex-snapshot
CLAmp‐seq: A Novel Amplicon‐Based NGS Assay with Concatemer Error Correction for Improved Detection of Actionable Mutations in Plasma cfDNA from Patients with NSCLC
inferred← citeshttps://doi.org/10.1002/tox.22390openalex-snapshot
Epidermal growth factor receptor (EGFR)—MAPK—nuclear factor(NF)‐κB—IL8: A possible mechanism of particulate matter(PM) 2.5‐induced lung toxicity
inferred← citeshttps://doi.org/10.1002/tox.22621openalex-snapshot
Effects and mechanisms of betulinic acid on improving EGFR TKI‐resistance of lung cancer cells
inferred← citeshttps://doi.org/10.1002/wsbm.1585openalex-snapshot
Evolution of precision oncology‐guided treatment paradigms
inferred← citeshttps://doi.org/10.1007/164_2017_16openalex-snapshot
Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1007/16833_2023_171openalex-snapshot
Combination of Stereotactic Ablative Radiotherapy and Systemic Therapy in Oligoprogressive Non-small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1007/174_2011_307openalex-snapshot
Systemic Therapy for Lung Cancer for the Radiation Oncologist
inferred← citeshttps://doi.org/10.1007/3-540-31040-1_6openalex-snapshot
Molecular Biology of Lung Cancer
inferred← citeshttps://doi.org/10.1007/7355_2016_26openalex-snapshot
Small Molecule Inhibitors of the Epidermal Growth Factor Receptor
inferred← citeshttps://doi.org/10.1007/7355_2020_100openalex-snapshot
Exploiting Kinase Inhibitors for Cancer Treatment: An Overview of Clinical Results and Outlook
inferred← citeshttps://doi.org/10.1007/978-0-387-69219-7_19openalex-snapshot
Update on the Role of EGFR Inhibitors in Cancer Therapeutics
inferred← citeshttps://doi.org/10.1007/978-0-387-69805-2_25openalex-snapshot
Oncogene Addiction: Mouse Models and Clinical Relevance for Molecularly Targeted Therapies
inferred← citeshttps://doi.org/10.1007/978-0-387-69805-2_27openalex-snapshot
Mouse Models of Human Cancer: Role in Preclinical Testing and Personalized Medicine
inferred← citeshttps://doi.org/10.1007/978-0-387-72114-9_2openalex-snapshot
Molecular Genetics of Lung and Pleural Neoplasms
inferred← citeshttps://doi.org/10.1007/978-0-387-73898-7_10openalex-snapshot
Clinical Development of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors: What Lessons Have We Learned?
inferred← citeshttps://doi.org/10.1007/978-0-387-89445-4_4openalex-snapshot
Mechanisms of Resistance to Targeted Tyrosine Kinase Inhibitors
inferred← citeshttps://doi.org/10.1007/978-0-387-93846-2_15openalex-snapshot
Somatic Genetic Alterations and Implications for Targeted Therapies in Cancer (GIST, CML, Lung Cancer)
inferred← citeshttps://doi.org/10.1007/978-1-4020-8442-3_20openalex-snapshot
Non-Small Cell Lung Carcinoma: EGFR Gene Mutations and Response to Gefitinib
inferred← citeshttps://doi.org/10.1007/978-1-4020-8442-3_21openalex-snapshot
Advanced Non-Small Cell Lung Carcinoma: Acquired Resistance to Gefitinib
inferred← citeshttps://doi.org/10.1007/978-1-4020-8442-3_27openalex-snapshot
Non-Small Cell Lung Cancer with Brain Metastasis: Role of Epidermal Growth Factor Receptor Gene Mutation
inferred← citeshttps://doi.org/10.1007/978-1-4419-0507-9_2openalex-snapshot
Signal Transduction Pathways as Therapeutic Targets in Cancer Therapy
inferred← citeshttps://doi.org/10.1007/978-1-4419-0772-1_15openalex-snapshot
Current Clinical Management of Metastatic Lung Cancer
inferred← citeshttps://doi.org/10.1007/978-1-4419-0787-5_14openalex-snapshot
Molecular Pathology of Lung Cancer
inferred← citeshttps://doi.org/10.1007/978-1-4419-6694-0_7openalex-snapshot
Somatic Evolution in Neoplastic Progression and Cancer Prevention
inferred← citeshttps://doi.org/10.1007/978-1-4419-7203-3_15openalex-snapshot
Epidermal Growth Factor Receptor-Targeted Therapies
inferred← citeshttps://doi.org/10.1007/978-1-4419-9755-5_3openalex-snapshot
Predictive Markers in Lung Cancer
inferred← citeshttps://doi.org/10.1007/978-1-4614-0598-6_11openalex-snapshot
Targeting Insulin-Like Growth Factor Receptor 1 (IGF-1R) and Insulin Receptor Signaling by Tyrosine Kinase Inhibitors in Cancer
inferred← citeshttps://doi.org/10.1007/978-1-4614-3197-8_9openalex-snapshot
Molecular Diagnosis of Lung Cancer
inferred← citeshttps://doi.org/10.1007/978-1-4614-5456-4_5openalex-snapshot
Predictive Biomarkers for Antibody–Drug Conjugates
inferred← citeshttps://doi.org/10.1007/978-1-4614-5847-0_3openalex-snapshot
Emerging Opportunities for Targeting the Tumor–Stroma Interactions for Increasing the Efficacy of Chemotherapy
inferred← citeshttps://doi.org/10.1007/978-1-4614-6176-0_3openalex-snapshot
Impact of Genetic Targets on Cancer Therapy in Esophagogastric Cancer
inferred← citeshttps://doi.org/10.1007/978-1-4614-8039-6_12openalex-snapshot
Domain Specific Targeting of Cancer
inferred← citeshttps://doi.org/10.1007/978-1-4614-8127-0_2openalex-snapshot
Epidermal Growth Factor Receptor Testing in Lung Adenocarcinoma
inferred← citeshttps://doi.org/10.1007/978-1-4899-8050-2_13openalex-snapshot
Molecular Testing in Pulmonary Tumors
inferred← citeshttps://doi.org/10.1007/978-1-4939-0727-4_24openalex-snapshot
Genomic Applications in Pulmonary Malignancies
inferred← citeshttps://doi.org/10.1007/978-1-4939-3073-9_1openalex-snapshot
HTRF Kinase Assay Development and Methods in Inhibitor Characterization
inferred← citeshttps://doi.org/10.1007/978-1-4939-3360-0_2openalex-snapshot
COLD-PCR: Applications and Advantages
inferred← citeshttps://doi.org/10.1007/978-1-4939-8958-4_2openalex-snapshot
Cancer Immunotherapy: The Dawn of Antibody Cocktails
inferred← citeshttps://doi.org/10.1007/978-1-4939-8973-7_4openalex-snapshot
Cell-Free DNA in the Liquid Biopsy Context: Role and Differences Between ctDNA and CTC Marker in Cancer Management
showing the first 200 of 3822 · page through all 3822
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.